Christopher Arendt, PhD, head of the Oncology Therapeutic Area Unit at Takeda, discusses pathogenesis and characteristics of EGFR exon 20 mutations in metastatic non–small cell lung cancer (NSCLC).
The EGFR exon 20 mutation in non–small cell lung cancer (NSCLC) is a progressive and genetic disease that can occur regardless of smoking history, with response to conventional chemotherapy tending to be very poor in these populations, said Christopher Arendt, PhD, head of the Oncology Therapeutic Area Unit at Takeda.
Transcript
Can you discuss the “mutually exclusive” nature of EGFR exon 20 mutations, which makes it important to find a treatment that can target them in metastatic NSCLC?
Absolutely, so let me start by stating that EGFR is a transmembrane growth factor kinase that's associated with alterations in different exon regions that are associated with NSCLCs. And so patients that have mutations in what's known as the exon 20 region have actually insertional mutation—so, extra genetic sequence that's located there that converts EGFR into an oncodriver to promote lung cancer.
What we mean by mutually exclusive is that it's defining patients who have a distinct subtype of disease in EGFR lung cancer and therefore require a specific targeted therapy in order to address that. In other words, it can't be addressed by the same medicines that would target, for example, an exon 20 defect or lesion in EGFR.
Can you discuss the populations most likely to have EGFR exon 20 mutations? Why are nonsmokers of particular interest?
Yeah, so it turns out that patients with exon 20 disease—so these exon 20–specific EGFR oncodriver mutations, who develop NSCLC as a result—these patients tend to be in the middle of their lives, in fact. Often they're either infrequent smokers or never smokers. It's a significant population of that EGFR space, that EGFR oncodriver space in lung cancer.
So, about 10% of patients who have an EGFR-driven lung cancer are ones who experience that through an exon 20–specific lesion. So, in terms of that connection to smoking, we know that smoking can drive genetic alterations in lung tissues that can lead to cancers, but when it comes to exon 20 disease, it's rather a genetic lottery.
You can think of it as sort of as this genetic lottery, one would pick up this lesion in lung tissue, again, sort of in midlife, and that can happen independent of your smoking history and result in a disease that's actually very devastating.
When you look across the different EGFR subtypes of disease, so, again, these lesions can occur in different exons, 19, 20, 21—those patients with the exon 20 insertional oncodriver mutations tend to have a worse prognosis within that EGFR cluster. And in fact, their responses to conventional chemotherapy tend to be very poor.
So, these patients are desperately in need of options, and that's why we're so excited and privileged really to be advancing what we hope can be the first orally available targeted medicine that can specifically address the needs of this patient population.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
Contributor: Maternal Health Outcomes Are a Systemic Signal
July 15th 2025Jayme Ambrose, DNP, RN, CCM, of Adobe Population Health, explores how addressing social determinants of health transforms maternal care delivery, reduces disparities, and improves outcomes for mothers and infants.
Read More